 "AstraZeneca Pharma soars over 40% in one week")
Shares of AstraZencea Pharma India have moved higher by 16% to Rs 1,274, extending its past four day’s over 20% rally on the BSE, on back of heavy volumes.
The stock opened at Rs 1,098 and touched a 52-week high of Rs 1,279 on the BSE so far. Till 1502 hours, about 181,398 shares changed hands against an average 31,000 shares that were traded daily in past two weeks on the BSE.
In past one-week the stock of pharmaceutical company has surged 41% from Rs 903 on June 8, compared to a marginal 0.37% rise in the S&P BSE Sensex.
On June 11, the company announced the launch of Forxiga (dapaglifozin), a breakthrough treatment for Type 2 diabetes mellitus, in the country.
Forxiga belongs to a new class of Type 2 diabetes mellitus medication-a highly selective inhibitor of sodium-glucose cotransporter 2 (SGLT2).
AstraZeneca Pharma Managing Director Sanjay Murdeshwar said the drug would offer an additional treatment option to over 63 million diabetes mellitus patients in India.
"Forxiga represents a significant advancement in the treatment of Type 2 diabetes mellitus with global safety and efficacy data of four years," he said.
The stock opened at Rs 1,098 and touched a 52-week high of Rs 1,279 on the BSE so far. Till 1502 hours, about 181,398 shares changed hands against an average 31,000 shares that were traded daily in past two weeks on the BSE.
In past one-week the stock of pharmaceutical company has surged 41% from Rs 903 on June 8, compared to a marginal 0.37% rise in the S&P BSE Sensex.
On June 11, the company announced the launch of Forxiga (dapaglifozin), a breakthrough treatment for Type 2 diabetes mellitus, in the country.
Forxiga belongs to a new class of Type 2 diabetes mellitus medication-a highly selective inhibitor of sodium-glucose cotransporter 2 (SGLT2).
AstraZeneca Pharma Managing Director Sanjay Murdeshwar said the drug would offer an additional treatment option to over 63 million diabetes mellitus patients in India.
"Forxiga represents a significant advancement in the treatment of Type 2 diabetes mellitus with global safety and efficacy data of four years," he said.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%